Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003960 · ClinicalTrials.gov registry record · Phase 2
Donor Bone Marrow Transplantation in Treating Patients With Hematologic Cancer
A Phase 2 study, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- Completed
- Registry status
- Phase 2
- Development phase
- 36
- Enrollment target
NCT00003960 is a Phase 2 study that has completed, run by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. The registered enrollment target is 36 participants.
The verdict
NCT00003960, a Phase 2 study, has completed, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 36 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Bone marrow transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy plus donor bone marrow transplantation in treating patients who have hematologic cancer.
Interventions
- DRUG cyclophosphamide
- DRUG methylprednisolone
- DRUG busulfan
- PROCEDURE allogeneic bone marrow transplantation
- PROCEDURE in vitro-treated bone marrow transplantation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 1998-04 |
| Est. Completion | 2001-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00003960
The ClinicalTrials.gov registry entry for NCT00003960 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which cyclophosphamide is the first listed.
NCT00003960 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00003960 about?
NCT00003960 is a clinical study titled "Donor Bone Marrow Transplantation in Treating Patients With Hematologic Cancer". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Bone marrow transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combin...
What is the current status of trial NCT00003960?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 36 participants. The study started on 1998-04. Estimated completion is 2001-09.
What interventions are being tested in trial NCT00003960?
The interventions under investigation include: cyclophosphamide (DRUG), methylprednisolone (DRUG), busulfan (DRUG), allogeneic bone marrow transplantation (PROCEDURE), in vitro-treated bone marrow transplantation (PROCEDURE).
Who is sponsoring clinical trial NCT00003960?
This trial is sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.